Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Nicola Maurea(Cancer Institute (WIA)), Carmela Coppola, Antônio Barbieri, Rolando Paciello(CEINGE Biotecnologie Avanzate Franco Salvatore (Italy)), Gennaro Riccio(Sapienza University of Rome), Domenica Rea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 32
Related Papers
Fish Waste: From Problem to Valuable Resource
|Marine Drugs|2021|568
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Microalgae with Immunomodulatory Activities
|Marine Drugs|2019|184
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108